132 related articles for article (PubMed ID: 36137845)
1. Contemporary primary treatment of women with stage II-IV low-grade serous ovarian/peritoneal cancer (LGSOC): Determinants of relapse and disease-free survival.
Gershenson DM; Cobb LP; Westin SN; Zhang Y; Jazaeri A; Malpica A; Sun CC
Gynecol Oncol; 2022 Nov; 167(2):139-145. PubMed ID: 36137845
[TBL] [Abstract][Full Text] [Related]
2. Impact of Age and Primary Disease Site on Outcome in Women With Low-Grade Serous Carcinoma of the Ovary or Peritoneum: Results of a Large Single-Institution Registry of a Rare Tumor.
Gershenson DM; Bodurka DC; Lu KH; Nathan LC; Milojevic L; Wong KK; Malpica A; Sun CC
J Clin Oncol; 2015 Aug; 33(24):2675-82. PubMed ID: 26195696
[TBL] [Abstract][Full Text] [Related]
3. Low-grade serous carcinoma (LGSC): A Canadian multicenter review of practice patterns and patient outcomes.
Scott SA; Llaurado Fernandez M; Kim H; Elit L; Nourmoussavi M; Glaze S; Roberts L; Offman SL; Rahimi K; Lytwyn A; Sur M; Gilks CB; Matheson K; Köbel M; Dawson A; Tinker AV; Kwon JS; Hoskins P; Santos JL; Cheung A; Provencher D; Carey MS;
Gynecol Oncol; 2020 Apr; 157(1):36-45. PubMed ID: 32001076
[TBL] [Abstract][Full Text] [Related]
4. Trends in the use of neoadjuvant chemotherapy for low-grade serous ovarian cancer in the United States.
Silberman JN; Bercow AS; Gockley AA; Eisenhauer EL; Sisodia R; Randall T; Del Carmen MG; Goodman A; Castro CM; Melamed A; Bregar AJ
Gynecol Oncol; 2023 Aug; 175():60-65. PubMed ID: 37327540
[TBL] [Abstract][Full Text] [Related]
5. Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum.
Gershenson DM; Bodurka DC; Coleman RL; Lu KH; Malpica A; Sun CC
J Clin Oncol; 2017 Apr; 35(10):1103-1111. PubMed ID: 28221866
[TBL] [Abstract][Full Text] [Related]
6. The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes.
Gershenson DM; Sun CC; Westin SN; Eyada M; Cobb LP; Nathan LC; Sood AK; Malpica A; Hillman RT; Wong KK
Gynecol Oncol; 2022 Jun; 165(3):560-567. PubMed ID: 35606067
[TBL] [Abstract][Full Text] [Related]
7. MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum.
Monk BJ; Grisham RN; Banerjee S; Kalbacher E; Mirza MR; Romero I; Vuylsteke P; Coleman RL; Hilpert F; Oza AM; Westermann A; Oehler MK; Pignata S; Aghajanian C; Colombo N; Drill E; Cibula D; Moore KN; Christy-Bittel J; Del Campo JM; Berger R; Marth C; Sehouli J; O'Malley DM; Churruca C; Boyd AP; Kristensen G; Clamp A; Ray-Coquard I; Vergote I
J Clin Oncol; 2020 Nov; 38(32):3753-3762. PubMed ID: 32822286
[TBL] [Abstract][Full Text] [Related]
8. Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer.
Patel A; Kalachand R; Busschots S; Doherty B; Kapros E; Lawlor D; Hall N; Stordal BK
Cochrane Database Syst Rev; 2022 Jul; 7(7):CD008766. PubMed ID: 35866378
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum.
Schmeler KM; Sun CC; Bodurka DC; Deavers MT; Malpica A; Coleman RL; Ramirez PT; Gershenson DM
Gynecol Oncol; 2008 Mar; 108(3):510-4. PubMed ID: 18155273
[TBL] [Abstract][Full Text] [Related]
10. Validation of Revised FIGO Staging Classification for Cancer of the Ovary, Fallopian Tube, and Peritoneum Based on a Single Histological Type.
Toptas T; Pestereli E; Erol O; Bozkurt S; Erdogan G; Simsek T
Int J Gynecol Cancer; 2016 Jul; 26(6):1012-9. PubMed ID: 27206284
[TBL] [Abstract][Full Text] [Related]
11. Carcinosarcoma of the ovary compared to ovarian high-grade serous carcinoma: impact of optimal cytoreduction and standard adjuvant treatment.
Yalcin I; Meydanli MM; Turan AT; Taskin S; Sari ME; Gungor T; Akbayir O; Ayhan A
Int J Clin Oncol; 2018 Apr; 23(2):329-337. PubMed ID: 29143144
[TBL] [Abstract][Full Text] [Related]
12. Advanced low grade serous ovarian cancer: A retrospective analysis of surgical and chemotherapeutic management in two high volume oncological centers.
Di Lorenzo P; Conteduca V; Scarpi E; Adorni M; Multinu F; Garbi A; Betella I; Grassi T; Bianchi T; Di Martino G; Amadori A; Maniglio P; Strada I; Carinelli S; Jaconi M; Aletti G; Zanagnolo V; Maggioni A; Savelli L; De Giorgi U; Landoni F; Colombo N; Fruscio R
Front Oncol; 2022; 12():970918. PubMed ID: 36237308
[TBL] [Abstract][Full Text] [Related]
13. Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?
Fader AN; Bergstrom J; Jernigan A; Tanner EJ; Roche KL; Stone RL; Levinson KL; Ricci S; Wethingon S; Wang TL; Shih IM; Yang B; Zhang G; Armstrong DK; Gaillard S; Michener C; DeBernardo R; Rose PG
Gynecol Oncol; 2017 Oct; 147(1):85-91. PubMed ID: 28768570
[TBL] [Abstract][Full Text] [Related]
14. The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer.
Crane EK; Sun CC; Ramirez PT; Schmeler KM; Malpica A; Gershenson DM
Gynecol Oncol; 2015 Jan; 136(1):25-9. PubMed ID: 25448453
[TBL] [Abstract][Full Text] [Related]
15. The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance.
Cobb LP; Sun CC; Iyer R; Nick AM; Fleming ND; Westin SN; Sood AK; Wong KK; Silva EG; Gershenson DM
Gynecol Oncol; 2020 Sep; 158(3):653-658. PubMed ID: 32709538
[TBL] [Abstract][Full Text] [Related]
16. Diagnosis-shift between low-grade serous ovarian cancer and serous borderline ovarian tumor: A population-based study.
Matsuo K; Machida H; Grubbs BH; Matsuzaki S; Klar M; Roman LD; Sood AK; Gershenson DM
Gynecol Oncol; 2020 Apr; 157(1):21-28. PubMed ID: 31954535
[TBL] [Abstract][Full Text] [Related]
17. Clinical factors associated with prognosis in low-grade serous ovarian carcinoma: experiences at two large academic institutions in Korea and Taiwan.
Kang JH; Lai YL; Cheng WF; Kim HS; Kuo KT; Chen YL; Lee YY
Sci Rep; 2020 Nov; 10(1):20012. PubMed ID: 33203969
[TBL] [Abstract][Full Text] [Related]
18. Impact of cytoreductive surgery on survival of patients with low-grade serous ovarian carcinoma: A multicentric study of Turkish Society of Gynecologic Oncology (TRSGO-OvCa-001).
Vatansever D; Taskiran C; Mutlu Meydanli M; Gungorduk K; Akbayir O; Yalcin I; Demirkiran F; Sozen H; Ozgul N; Celik H; Onan MA; Taskin S; Oge T; Simsek T; Abboud S; Yuksel IT; Ayhan A
J Surg Oncol; 2021 May; 123(8):1801-1810. PubMed ID: 33657253
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of supraclavicular lymphadenopathy in patients with high-grade serous ovarian cancer.
Cybulska P; Hayes SA; Spirtos A; Rafizadeh MJ; Filippova OT; Leitao M; Zivanovic O; Sonoda Y; Mueller J; Lakhman Y; Long K; Chi DS
Int J Gynecol Cancer; 2019 Nov; 29(9):1377-1380. PubMed ID: 31575614
[TBL] [Abstract][Full Text] [Related]
20. Retrospective analysis of uterine involvement in low grade serous ovarian carcinoma.
Petiot F; Descargues P; Devouassoux-Shisheboran M; You B; Rousset-Jablonski C; Raffin D; Hajri T; Gertych W; Glehen O; Philip CA; Lamblin G; Golfier F; Bolze PA
Eur J Obstet Gynecol Reprod Biol; 2024 Mar; 294():191-197. PubMed ID: 38295707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
